ImmuPharma (IMM) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free IMM Stock Alerts GBX 2.37 -0.01 (-0.42%) (As of 04:21 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 8, 2024 | msn.comInvestigational Drugs for Chronic Inflammatory Demyelinating PolyneuropathyMay 8, 2024 | msn.comLooking for top FTSE 100 value shares? Here’s one I’d buy without hesitationApril 2, 2024 | lse.co.ukImmupharma jumps amid new IP strategy for P140 technology platformMarch 25, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesMarch 15, 2024 | msn.comSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 8, 2024 | finance.yahoo.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsFebruary 24, 2024 | morningstar.comImmuPharma PLC IMMFebruary 21, 2024 | lse.co.ukUK government borrowing surplus rises in January from prior yearJanuary 17, 2024 | ca.finance.yahoo.comImmuPharma PLC (25I.SG)December 19, 2023 | lse.co.ukEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsAugust 31, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | marketwatch.comImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 21, 2023 | lse.co.ukImmuPharma agrees 12 month extension to Incanthera warrant instrumentJune 27, 2023 | proactiveinvestors.comImmuPharma "absolutely delighted" to push on with new clinical trialJune 19, 2023 | proactiveinvestors.comImmuPharma presses on with next phase of Lupuzor clinical trialsMay 24, 2023 | proactiveinvestors.comImmuPharma "looking forward with quiet confidence" to FDA responseMay 18, 2023 | uk.investing.comFTSE 100 remains higher but off best with Wall Street indicated mixedMay 18, 2023 | marketwatch.comImmuPharma Shares Rise on Positive Guidance From US FDA for P140May 18, 2023 | proactiveinvestors.comImmuPharma shares jump 6.5% after FDA updateMay 18, 2023 | proactiveinvestors.comImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorMay 12, 2023 | marketwatch.comSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029May 11, 2023 | proactiveinvestors.comImmuPharama eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma eyes clinical trial progressApril 27, 2023 | proactiveinvestors.comImmuPharma "looking forward" to upcoming FDA meetingsApril 19, 2023 | proactiveinvestors.comImmuPharma partner gets FDA meeting dateApril 12, 2023 | marketwatch.comImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical ProgramApril 12, 2023 | proactiveinvestors.comImmuPharma rises 4% after it reveals headway with lead assetApril 12, 2023 | proactiveinvestors.comImmuPharma makes progress developing second indication for lead assetMarch 30, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Top Players By 2031March 27, 2023 | proactiveinvestors.comImmuPharma: US partner has submitted Lupuzor phase II/III trial protocolMarch 27, 2023 | marketwatch.comImmuPharma Shares Rise on Lupus Candidate FDA Trial SubmissionMarch 27, 2023 | proactiveinvestors.comImmuPharma: US partner submits Lupuzor phase II/III trial protocolMarch 6, 2023 | proactiveinvestors.comImmuPharma collaborates on potential 'radioactive bullet' to kill cancerFebruary 14, 2023 | marketwatch.comCutaneous Lupus Erythematosus (CLE) Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of SolutionsFebruary 8, 2023 | proactiveinvestors.comImmuPharma expects new Lupozor study to begin in H2 2023February 6, 2023 | lse.co.ukImmuPharma agrees study design with Avion for lupus programme LupuzorFebruary 6, 2023 | marketwatch.comImmuPharma Shares Rise After Lupuzor Trial ConfirmedFebruary 6, 2023 | proactiveinvestors.comImmuPharma partner agrees phase II/III clinical trial processJanuary 10, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Size 2023 Report Examines Latest Trends and Key Drivers Supporting Regional Outlook 2028December 22, 2022 | fxstreet.comUK data highlights oncoming recessionDecember 22, 2022 | marketwatch.comImmuPharma Shares Rise After Executives Waive Part of SalaryDecember 22, 2022 | proactiveinvestors.comImmuPharma says it has ‘clear objective’ to advance lupus treatment to next clinical trial in 2023November 11, 2022 | proactiveinvestors.comImmupharma’s US partner confirms support for lupus treatment and wants to expand collaborationNovember 11, 2022 | proactiveinvestors.comImmupharma’s US partner confirms support for lupus treatment, wants to expand collaborationOctober 13, 2022 | finance.yahoo.comAfter losing 57% in the past year, ImmuPharma plc (LON:IMM) institutional owners must be relieved by the recent gainOctober 6, 2022 | morningstar.co.ukTRADING UPDATES: ImmuPharma loss narrows; MetalNRG... - MorningstarOctober 6, 2022 | finance.yahoo.comImmuPharma plc (IMM.L)September 30, 2022 | proactiveinvestors.comImmuPharma said it welcomes 'helpful' FDA recommendations ahead of phase III study - Proactive Investors USASeptember 30, 2022 | proactiveinvestors.comImmuPharma says it welcomes 'helpful' FDA recommendations ahead of phase III study - Proactive Investors USASeptember 14, 2022 | proactiveinvestors.comUS markets end a roller coaster session in positive territory - Proactive Investors USA Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. IMM Media Mentions By Week IMM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.680.56▲Average Medical News Sentiment IMM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼20▲IMM Articles Average Week Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BVX News ROQ News VAL News SNG News IXI News EVG News FAB News OBI News DEST News ONC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:IMM) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill PublishingTop 5 Tech Stocks to Buy for 2024Daily Market AlertsTop 5 AI Stocks to Buy for 2024Market Moving Trendsis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
